Author: Taco Tuinstra

  • FDA Urged to Act on Remaining PMTA Submissions

    FDA Urged to Act on Remaining PMTA Submissions

    Photo: New Africa

    Several anti-tobacco groups have sent a letter to the U.S. Food and Drug Administration urging the agency to act on the outstanding premarket tobacco product applications (PMTAs) and pushing for the denial of all flavored e-cigarette products.

    It’s been more than four months since the FDA was supposed to decide which e-cigarette products can remain on the market, but the agency still hasn’t completed some of the reviews, including some of the bestselling e-cigarettes.

    “We write to urge the U.S. Food and Drug Administration (FDA) to expedite decisions on the premarket tobacco product applications (PMTAs) still pending before the agency involving the flavored e-cigarette products, including those with menthol flavoring and, based on the best available scientific evidence, deny the pending applications for all non-tobacco flavored e-cigarettes in order to protect the nation’s young people from the health harms of these products,” the letter said.

    The letter was signed by the American Academy of Pediatrics, the American Heart Association and the Campaign for Tobacco-Free Kids, among others.

    “Every day that FDA delays action, more of our kids remain at risk,” said Matthew Myers, president of the Campaign for Tobacco-Free Kids. “While the FDA has ruled on applications from a lot of small companies, it hasn’t ruled on the applications from the large companies whose products are being used by a majority of kids.”

    American Vaping Association President Gregory Conley pointed to data showing that youth vaping has been declining. According to the Centers for Disease Control and Prevention (CDC), use of e-cigarettes went down among middle and high school students from 2019 to 2020.

    But even with the drop, the CDC said it “estimated that more than 2 million U.S. middle and high school students reported currently using e-cigarettes in 2021.”

  • Lithuania Bans Non-Tobacco Flavored E-Cigarettes

    Lithuania Bans Non-Tobacco Flavored E-Cigarettes

    Photo: MNStudio

    Lithuania will ban the sale of flavored e-cigarettes and e-liquid cartridges starting in July, reports LRT. Tobacco flavors will remain legal.

    The move is aimed at reducing sales of e-cigarettes that are growing increasingly popular in Lithuania.

    On Jan. 18, Lithuanian lawmakers adopted amendments to the Law on Control of Tobacco, Tobacco Products and Related Products with 92 votes in favor, nine against and nine abstentions.

    Lithuania already bans vaping hardware and cartridges containing vitamins and other additives that create an impression that they are good or do less damage to health.

    The country also prohibits imports of e-cigarettes and e-liquid cartridges containing caffeine and other stimulating compounds linked to energy and vitality.

  • BAT Launches Virtual R&D Visitor Experience

    BAT Launches Virtual R&D Visitor Experience

    Image: BAT

    BAT has created a virtual R&D visitor experience, an online tour of its global research and development hub in Southampton, U.K., that allows people to explore its cutting-edge science and innovation.

    BAT says the experience builds on the company’s open and transparent approach to the science underpinning its reduced-risk product portfolio and beyond nicotine activities. The company regularly welcomes visitors in person to its global R&D hub, with more than 3,500 people viewing the facilities firsthand since 2011. However, with travel significantly reduced, the virtual experience allows people from across the globe to access and understand BAT’s scientific research and tobacco harm reduction activities and gain perspectives and insights from experts.

    “At BAT, R&D is fundamental to what we do,” said David O’Reilly, director of scientific research at BAT, in a statement. “Our focus on science and research has enabled us to make significant progress in developing and evolving our New Category products, which are rigorously tested and scientifically substantiated as reduced-risk alternatives to cigarettes. Our R&D is based around consumer preferences as well as applying evolving science and innovation to our products. This allows us to offer a range of enjoyable reduced-risk alternatives to cigarettes while ensuring we maintain very high safety and quality standards.

    “Our new R&D virtual visitor experience demonstrates the breadth of science we are undertaking and the robust scientific framework we use to evaluate and support the role our products play in delivering tobacco harm reduction.”

    With 360-degree lab tours, animations, videos, scientist profiles, podcasts and more, the R&D virtual visitor experience is the one-stop hub for those looking to find out about BAT’s science. The tour illuminates BAT’s purpose to build “A Better Tomorrow” and mission to reduce the health impact of its business. BAT invests almost £350 million [$477.18 million] a year to find innovative ways to reduce its effects on public health and aims to have 50 million consumers of its noncombustible products by 2030.